Italian antitrust authorities are suspecting drug giants Novartis and Roche of a cartel and have launched an investigation into the matter, according to reports. The Italian Competition Authority is looking into whether the companies colluded to keep a drug off the shelves to leave space for a more expensive drug. Reports say the companies worked to keep Avastin, a drug to tread wet age related macular degeneration, off shelves to promote Lucentis, a more expensive but approved drug. Two complaints over the matter were filed to authorities by a private healthcare association and the Italian Opthalmological Society. The two companies in question are based in Switzerland.
Featured News
Paul Weiss Pushes Back Against Removal Bid in Sugar Antitrust Fight
Sep 24, 2026 by
CPI
Saudi Arabia Reviews Uber’s $14.8 Billion Delivery Hero Takeover
Sep 24, 2026 by
CPI
Pope Leo Warns of AI Threats, Calls for Stronger Global Oversight
Sep 24, 2026 by
CPI
Paramount-Warner Bros. Discovery Merger Settlement Faces Coalition Challenge
Sep 24, 2026 by
CPI
New York Grocery Plan Puts Predatory-Pricing Rules to the Test
Sep 24, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – National Security
Sep 22, 2026 by
CPI
National Security in U.S. Antitrust Enforcement: Toward a More Disciplined Framework
Sep 22, 2026 by
Rod Rosenstein & Timothy Finley
The Department of War’s M&A Review Guidance: What Companies in the Defense Industry Need to Know
Sep 22, 2026 by
Eric Stocking & Paul Ney
National Security, Resilience and the Boundaries of Merger Control
Sep 22, 2026 by
Beatriz Marques
National Security and Competition: Building Resilient Telecommunications Networks
Sep 22, 2026 by
Roslyn Layton